Hiroshi Shibata
Tokushima, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 35 publications
Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib.
Journal: Scientific reports
Published: October 18, 2023
Comparison between Atezolizumab Plus Bevacizumab and Lenvatinib for Hepatocellular Carcinoma in Patients with Child-Pugh Class B in Real-World Clinical Settings.
Journal: Oncology
Published: November 07, 2022
Multicenter retrospective study of initial treatment outcome and feasibility of initiating dose reduction of cabozantinib in unresectable hepatocellular carcinoma.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: June 28, 2022
Simple Scoring System for Predicting TACE Unsuitable among Intermediate-Stage Hepatocellular Carcinoma Patients in the Multiple Systemic Treatment Era.
Journal: Oncology
Published: September 21, 2021
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.
Impact of modified albumin-bilirubin grade on survival in patients with HCC who received lenvatinib.
Journal: Scientific reports
Published: June 01, 2021
Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib.
Journal: Liver international : official journal of the International Association for the Study of the Liver
Published: May 25, 2021
Efficacy of lenvatinib for unresectable hepatocellular carcinoma based on background liver disease etiology: multi-center retrospective study.
Journal: Scientific reports
Published: April 05, 2021
Impact of Early Lenvatinib Administration on Survival in Patients with Intermediate-Stage Hepatocellular Carcinoma: A Multicenter, Inverse Probability Weighting Analysis.
Journal: Oncology
Published: February 22, 2021
Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression.
Journal: Hepatology research : the official journal of the Japan Society of Hepatology
Published: December 03, 2020
Real-World Virological Efficacy and Safety of Ledipasvir and Sofosbuvir in Patients with Chronic Hepatitis C Virus Genotype 2 Infection: A Multicenter Study.
Journal: Infectious diseases and therapy
Published: September 26, 2020
Last Updated: 09/26/2026